Medicus Pharma Ltd (MDCX)

Jun 22, 2026, 7:30 AM EDT - 12 days ago

Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026

2026-06-15T11:51:23.000Z - 19 days ago

Medicus submits SkinJect Rare Pediatric Disease Designation request to FDA

Jun 15, 2026, 7:30 AM EDT - 19 days ago

Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome

Jun 11, 2026, 7:30 AM EDT - 23 days ago

Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program

UAE

2026-06-08T11:37:41.000Z - 26 days ago

Medicus Pharma submits substantial modification application through EU CTIS

Jun 8, 2026, 7:30 AM EDT - 26 days ago

Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission

2026-06-03T13:37:23.000Z - 4 weeks ago

Medicus Pharma submits Protocol SKNJCT-005 to the FDA

Jun 3, 2026, 8:00 AM EDT - 4 weeks ago

Medicus Pharma Advances SkinJect® into Registrational Development for Gorlin Syndrome

May 28, 2026, 8:00 AM EDT - 5 weeks ago

Medicus Pharma Announces $22 Million Non-Dilutive Financing

2026-05-14T22:18:41.000Z - 7 weeks ago

Medicus Pharma reports Q1 EPS (31c), consensus (22c)

May 14, 2026, 4:30 PM EDT - 7 weeks ago

Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

2026-05-07T03:48:38.000Z - 2 months ago

Medicus Pharma announces results from Phase 2 SKNJCT-003 analysis

May 6, 2026, 7:30 AM EDT - 2 months ago

Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response

2026-04-27T13:31:02.000Z - 2 months ago

Medicus Pharma meets with lawmakers to support SkinJect designations

Apr 27, 2026, 7:30 AM EDT - 2 months ago

Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill

2026-04-21T11:53:55.000Z - 2 months ago

Medicus Pharma initiated with a Buy at Roth Capital

2026-04-17T11:35:50.000Z - 2 months ago

Medicus Pharma submits ODD application to U.S. FDA for SkinJect

Apr 17, 2026, 7:30 AM EDT - 2 months ago

Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome

Apr 15, 2026, 7:30 AM EDT - 2 months ago

Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression

2026-04-07T14:23:02.000Z - 3 months ago

Medicus Pharma enters media partnership with New to The Street

2026-04-06T11:37:11.000Z - 3 months ago

Medicus Pharma submits clinical study design to FDA for Teverelix

Apr 6, 2026, 7:30 AM EDT - 3 months ago

Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention

Apr 1, 2026, 7:30 AM EDT - 3 months ago

Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset

2026-03-30T13:38:08.000Z - 3 months ago

Medicus Pharma reports principal investigator validation of Phase 2 data

Mar 30, 2026, 7:30 AM EDT - 3 months ago

Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate

Mar 26, 2026, 7:30 AM EDT - 3 months ago

Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan

Mar 25, 2026, 4:30 PM EDT - 3 months ago

Medicus Pharma Reports Full-Year 2025 Financial Results and Provides Corporate Update

2026-03-18T11:52:25.000Z - 3 months ago

Medicus Pharma to discuss Skinject Phase 2 reults in fireside chat

Mar 18, 2026, 7:30 AM EDT - 3 months ago

Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst

2026-03-16T11:50:31.000Z - 3 months ago

Medicus Pharma announces SkinJect Phase 2 KOL update

Mar 16, 2026, 7:30 AM EDT - 3 months ago

Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26

Mar 10, 2026, 7:30 AM EDT - 4 months ago

Medicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum

2026-03-09T11:40:33.000Z - 4 months ago

Medicus Pharma provides interpretation of Phase 2 SkinJect dataset

Mar 9, 2026, 7:30 AM EDT - 4 months ago

Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset

2026-03-05T13:10:22.000Z - 4 months ago

Medicus Pharma announces results from Phase 2 study of D-MNA

2026-03-05T12:35:46.000Z - 4 months ago

Medicus Pharma announces results from Phase 2 study of D-MNA

Mar 5, 2026, 7:30 AM EST - 4 months ago

Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort

Mar 3, 2026, 7:30 AM EST - 4 months ago

Medicus Pharma To Participate in the 38th Annual Roth Conference

Feb 12, 2026, 7:30 AM EST - 5 months ago

Medicus Pharma on Bloomberg World

2026-02-10T13:40:50.000Z - 5 months ago

Medicus signs six-part media series with New to the Street

2026-02-10T12:35:27.000Z - 5 months ago

Medicus receives FDA ‘study may proceed’ clearance for Teverelix Phase 2b study

Feb 10, 2026, 7:30 AM EST - 5 months ago

Medicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk

Jan 23, 2026, 7:30 AM EST - 5 months ago

Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony

2026-01-22T12:35:45.000Z - 5 months ago

Medicus announces amendment to LifeArc license improving Teverelix profile

Jan 22, 2026, 7:30 AM EST - 5 months ago

Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile

Jan 20, 2026, 7:30 AM EST - 5 months ago

Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026

2026-01-12T12:50:08.000Z - 6 months ago

Medicus Pharma announces clinical data on Teverelix

Jan 12, 2026, 7:30 AM EST - 6 months ago

Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women

Jan 5, 2026, 7:30 AM EST - 6 months ago

Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates

Dec 22, 2025, 7:30 AM EST - 6 months ago

Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform

Dec 15, 2025, 7:30 AM EST - 7 months ago

Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Dec 5, 2025, 3:20 PM EST - 7 months ago

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement

Dec 1, 2025, 8:00 AM EST - 7 months ago

Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President

Nov 24, 2025, 8:00 AM EST - 7 months ago

Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers

Nov 17, 2025, 7:30 AM EST - 8 months ago

Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Nov 14, 2025, 5:00 PM EST - 8 months ago

Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights

Nov 13, 2025, 7:30 AM EST - 8 months ago

Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Oct 29, 2025, 7:30 AM EDT - 8 months ago

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome

Oct 29, 2025, 7:30 AM EDT - 8 months ago

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome

Oct 22, 2025, 7:30 AM EDT - 9 months ago

Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Oct 14, 2025, 8:07 AM EDT - 9 months ago

The Vanderbilt Report: Medicus Pharma Ltd Built Three Separate Billion-Dollar Bets

Oct 13, 2025, 7:30 AM EDT - 9 months ago

Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025

Oct 7, 2025, 7:30 AM EDT - 9 months ago

Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE

Sep 29, 2025, 7:30 AM EDT - 9 months ago

Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject

Sep 24, 2025, 9:26 AM EDT - 10 months ago

Stonegate Capital Partners Initiates Coverage on Medicus Pharma Ltd. (MDCX)

Sep 24, 2025, 7:30 AM EDT - 10 months ago

Medicus Pharma Ltd. To Present at Brookline Capital Markets

Sep 18, 2025, 7:30 AM EDT - 10 months ago

Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing

Sep 8, 2025, 7:30 AM EDT - 10 months ago

Medicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Sep 2, 2025, 7:30 AM EDT - 10 months ago

Medicus Pharma Ltd. Completes Acquisition of Antev Limited

Aug 21, 2025, 7:30 AM EDT - 11 months ago

Medicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Second Quarter 2025 Financial Highlights